Citadel Advisors
BIVI icon

Citadel Advisors’s BioVie BIVI Stock Holding History

Citadel Advisors’s Portfolio BIVI Stock Details BIVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-107
Closed -$4.29K – 14258
2024
Q2 		$4.29K Sell
107
-337
-76% -$16.1K ﹤0.01% 13500
2024
Q1 		$23.5K Buy
444
+404
+1,010% +$41.4K ﹤0.01% 12895
2023
Q4 		$5.04K Sell
40
-25
-38% -$7.51K ﹤0.01% 13461
2023
Q3 		$22.2K Sell
65
-96
-60% -$37.5K ﹤0.01% 12544
2023
Q2 		$69.4K Sell
161
-54
-25% -$36.4K ﹤0.01% 11405
2023
Q1 		$174K Buy
+215
New +$142K ﹤0.01% 10408

Other funds holding BIVI

DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PTC
Philadelphia Trust Company Philadelphia, Pennsylvania $1.42B AUM 43.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors's BIVI Position: Q1 2026 in Review

Citadel Advisors increased its BioVie (BIVI) stake by 150% in Q1 2026, buying an estimated $34.9K and bringing the position to 45,292 shares worth $63.4K. The position accounts for ﹤0.01% of the portfolio, ranked #12301.

Citadel Advisors first reported a position in BIVI in Q4 2022 and has held it in 6 quarters since. The position peaked at $199K in Q3 2025. 33 funds tracked by Wall St. Rank hold BIVI as of Q1 2026.

  • Citadel Advisors held 45,292 shares of BioVie worth $63.4K as of Q1 2026.
  • Citadel Advisors bought 27,142 BioVie shares in Q1 2026, an estimated $34.9K.
  • BioVie made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12301 holding.
  • Citadel Advisors first reported a position in BioVie in Q4 2022 and has held it in 6 quarters since.
  • Citadel Advisors's BioVie position peaked at $199K in Q3 2025.
  • 33 funds tracked by Wall St. Rank held BioVie as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.